8th December, 2021Thelper is pleased to announce that we have received 50% funding coverage from the Norwegian Research Council in December 2021 for the Industrial PhD project: “Development and preclinical documentation of First-in-Class Immunotherapy against triple negative breast cancer”, which will run from 2022 to 2026.